Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 5:16:930613.
doi: 10.3389/fnins.2022.930613. eCollection 2022.

Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice

Se Jong Oh  1 , Namhun Lee  1 , Kyung Rok Nam  1 , Kyung Jun Kang  1 , Sang Jin Han  1 , Kyo Chul Lee  1 , Yong Jin Lee  1 , Jae Yong Choi  1   2
Affiliations

Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice

Se Jong Oh et al. Front Neurosci. .

Erratum in

Abstract

This study aimed to investigate how amyloid pathology affects the functional aspects of neurotransmitter systems in Alzheimer's disease. APPswe/PS2 mice (21 months of age) and wild-type (WT) mice underwent positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). First, we obtained 18F-FDG and 18F-florbetaben PET scans to evaluate neuronal integrity and amyloid pathology. Second, 18F-FPEB and 18F-FMZ PET data were acquired to assess the excitatory-inhibitory neurotransmission. Third, to monitor the dopamine system, 18F-fallypride PET was performed. Amyloid PET imaging revealed that radioactivity was higher in the AD group than that in the WT group, which was validated by immunohistochemistry. In the cortical and limbic areas, the AD group showed a 25-27% decrease and 14-35% increase in the glutamatergic and GABAergic systems, respectively. The dopaminergic system in the AD group exhibited a 29% decrease in brain uptake compared with that in the WT group. A reduction in glutamate, N-acetylaspartate, and taurine levels was observed in the AD group using MRS. Our results suggest that dysfunction of the neurotransmitter system is associated with AD pathology. Among the systems, the GABAergic system was prominent, implying that the inhibitory neurotransmission system may be the most vulnerable to AD pathology.

Keywords: APPswe/PS2; Alzheimer’s disease; beta amyloid; neurotransmitter; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Definition of volumes of interest (VOIs) for all positron emission tomography (PET) tracers. Magnetic resonance (MR) images for the horizontal, coronal, and sagittal planes are presented. Spatially normalized PET images were applied to the VOIs for each radiotracer.
FIGURE 2
FIGURE 2
Summed positron emission tomography (PET) images (40–60 min) of 18F-FDG in the wild-type (WT) (A–C) and Alzheimer’s disease (AD) groups (D–F). In PET images, the columns from left to right show the axial, coronal, and sagittal views. Comparison of the standardized uptake values (SUVs) in terms of the target regions (G). Data are presented as the mean ± SD (n = 6).
FIGURE 3
FIGURE 3
Summed positron emission tomography (PET) images (10–30 min) of 18F-florbetaben in the wild-type (WT) (A–C) and Alzheimer’s disease (AD) groups (D–F). Comparison of the standardized uptake values (SUVs) for the brain regions (G) at 10–30 min. Values are presented as the mean ± SD (n = 6). Statistical significance was defined as a p value less than 0.05 for comparisons between groups (*p < 0.05, ***p < 0.001 and ****p < 0.0001).
FIGURE 4
FIGURE 4
Mean positron emission tomography (PET) images of 18F-FPEB [wild-type (WT) (A–C) and Alzheimer’s disease (AD) (D–F) at 40–60 min] and 18F-flumazenil [WT (G–I) and AD (J–L) at 30–50 min]. Quantification of the radioactivities for the 18F-FPEB (M) and 18F-flumazenil (N). Data are presented as the mean ± SD (n = 6). Statistical significance was defined as a p value less than 0.05 for comparisons between groups (**p < 0.01, ***p < 0.001, and ****p < 0.0001).
FIGURE 5
FIGURE 5
Mean positron emission tomography (PET) images of 18F-fallypride for wild-type (WT) (A–C) and Alzheimer’s disease (AD) groups (D–F). Comparison of the standardized uptake values (SUVs) for the striatum and cerebellum for 18F-fallypride at 30–50 min (G). Data are presented as the mean ± SD (n = 6). Statistical significance was defined as a p value less than 0.05 for comparisons between groups (****p < 0.0001).
FIGURE 6
FIGURE 6
Immunohistochemical staining of Aβ42 peptide in the hippocampus for wild-type (WT) and Alzheimer’s disease (AD) mice (A–H). (A,B) 100× magnification of the hippocampus, (C–H) 400× magnification of the hippocampal regions such as CA1, CA2, and CA3 (Scale bar = 60 μm). The number of Aβ42 peptides in the CA1, CA2, and CA3 regions are expressed as mean ± SD (I, *p < 0.05, and **p < 0.005). This analysis was done for all mice (n = 5).
FIGURE 7
FIGURE 7
Definition of the volume of interest (i.e., dorsal hippocampus) in magnetic resonance spectroscopy (MRS) (A). Comparison of the neurochemical profiles between the wild-type (WT) and APPswe/PS2 mice (B). Data are presented as the mean ± SD (n = 5). A p-value < 0.05 was considered statistically significant (*p < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Antuono P. G., Jones J. L., Wang Y., Li S. J. (2001). Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1H-MRS at 0.5 T. Neurology 56 737–742. 10.1212/WNL.56.6.737 - DOI - PubMed
    1. Barnard E. A., Skolnick P., Olsen R. W., Mohler H., Sieghart W., Biggio G., et al. (1998). International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acidA receptors: Classification on the basis of subunit composition, pharmacology, and function. Pharmacol. Rev. 50 291–313. - PubMed
    1. Brendel M., Jaworska A., Grießinger E., Rötzer C., Burgold S., Gildehaus F. J., et al. (2015). Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS One 10:e0116678. 10.1371/journal.pone.0116678 - DOI - PMC - PubMed
    1. Costantini L. C., Barr L. J., Vogel J. L., Henderson S. T. (2008). Hypometabolism as a therapeutic target in Alzheimer’s disease. BMC Neurosci. 9 (Suppl. 2):S16. 10.1186/1471-2202-9-S2-S16 - DOI - PMC - PubMed
    1. Dixon R. M., Bradley K. M., Budge M. M., Styles P., Smith A. D. (2002). Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease. Brain 125 2332–2341. 10.1093/brain/awf226 - DOI - PubMed

LinkOut - more resources